Monte Rosa Financials

GLUE Stock  USD 5.83  0.03  0.52%   
Based on the key measurements obtained from Monte Rosa's financial statements, Monte Rosa Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At present, Monte Rosa's Total Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 327.7 M, whereas Other Current Liabilities is forecasted to decline to about 14.2 M. Key indicators impacting Monte Rosa's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio2.282.4049
Notably Down
Slightly volatile
The financial analysis of Monte Rosa is a critical element in measuring its lifeblood. Investors should not minimize Monte Rosa's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.

Net Income

(76.33 Million)

  
Understanding current and past Monte Rosa Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Monte Rosa's financial statements are interrelated, with each one affecting the others. For example, an increase in Monte Rosa's assets may result in an increase in income on the income statement.
Please note, the presentation of Monte Rosa's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Monte Rosa's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Monte Rosa's management manipulating its earnings.

Monte Rosa Stock Summary

Monte Rosa competes with Nkarta, Lyell Immunopharma, Generation Bio, Sana Biotechnology, and Design Therapeutics. Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the bodys natural mechanisms to selectively degrade therapeutically relevant proteins. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts. Monte Rosa operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 93 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS61225M1027
CUSIP61225M102
LocationMassachusetts; U.S.A
Business Address321 Harrison Avenue,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.monterosatx.com
Phone617 949 2643
CurrencyUSD - US Dollar

Monte Rosa Key Financial Ratios

Monte Rosa Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets49.4M366.3M342.4M303.8M438.7M277.1M
Other Current Liab22.2M10.1M11.5M14.6M18.8M14.2M
Net Debt26.1M(346.1M)(7.9M)(82.1M)(181.5M)(172.5M)
Retained Earnings(48.1M)(122.0M)(230.5M)(365.9M)(438.6M)(416.7M)
Accounts Payable7.1M6.6M7.9M11.2M17.2M9.7M
Cash41.7M346.1M54.9M128.1M224.3M146.9M
Other Current Assets1.8M5.2M5.4M3.3M5.1M3.9M
Total Liab98.1M18.8M71.0M124.5M215.8M226.6M
Net Invested Capital(48.7M)347.5M271.4M179.3M222.9M176.2M
Total Current Assets43.6M348.7M275.9M236.2M377.4M236.8M
Net Working Capital14.3M332.0M250.3M189.6M220.5M185.6M

Monte Rosa Key Income Statement Accounts

202020212022202320242025 (projected)
Net Interest Income9K46K3.8M9.0M10.6M11.1M
Gross Profit(537K)(2.1M)(8.6M)(6.2M)75.6M79.4M
Operating Income(28.0M)(72.9M)(112.4M)(143.3M)(81.1M)(85.2M)
Ebit(28.0M)(72.9M)(108.5M)(143.3M)(129.0M)(122.5M)
Research Development24.0M57.2M85.1M105.1M121.6M73.4M
Ebitda(27.5M)(70.8M)(99.9M)(137.1M)(81.1M)(85.2M)
Cost Of Revenue537K2.1M8.6M6.2M7.2M3.9M
Income Before Tax(35.9M)(74.0M)(108.5M)(135.0M)(70.1M)(73.6M)
Net Income(36.1M)(71.9M)(104.6M)(135.4M)(72.7M)(76.3M)
Income Tax Expense189K(2.0M)(3.9M)338K2.6M2.7M

Monte Rosa Key Cash Accounts

202020212022202320242025 (projected)
Investments(3.4M)(9.7M)(206.4M)20.6M(44.5M)(46.7M)
Change In Cash33.6M308.5M(291.2M)72.5M96.4M101.3M
Free Cash Flow(26.4M)(69.1M)(105.4M)(62.8M)38.0M39.9M
Depreciation537K2.1M3.7M6.2M8.1M8.5M
Other Non Cash Items7.7M960K2.8M(3.8M)(2.9M)(2.8M)
Capital Expenditures3.4M9.7M12.9M19.0M4.0M3.8M
Net Income(35.9M)(74.0M)(108.5M)(135.4M)(72.7M)(76.3M)
End Period Cash Flow42.9M351.4M60.2M132.7M229.1M151.3M

Monte Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Monte Rosa's current stock value. Our valuation model uses many indicators to compare Monte Rosa value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Monte Rosa competition to find correlations between indicators driving Monte Rosa's intrinsic value. More Info.
Monte Rosa Therapeutics is rated below average in return on equity category among its peers. It is one of the top stocks in return on asset category among its peers . At present, Monte Rosa's Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Monte Rosa by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Monte Rosa Therapeutics Systematic Risk

Monte Rosa's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Monte Rosa volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Monte Rosa Therapeutics correlated with the market. If Beta is less than 0 Monte Rosa generally moves in the opposite direction as compared to the market. If Monte Rosa Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Monte Rosa Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Monte Rosa is generally in the same direction as the market. If Beta > 1 Monte Rosa moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Monte Rosa Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Monte Rosa's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Monte Rosa growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.12

At present, Monte Rosa's Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting.

Monte Rosa March 25, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Monte Rosa help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Monte Rosa Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Monte Rosa Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Monte Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Monte Rosa's daily price indicators and compare them against related drivers.

Complementary Tools for Monte Stock analysis

When running Monte Rosa's price analysis, check to measure Monte Rosa's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monte Rosa is operating at the current time. Most of Monte Rosa's value examination focuses on studying past and present price action to predict the probability of Monte Rosa's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monte Rosa's price. Additionally, you may evaluate how the addition of Monte Rosa to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Commodity Directory
Find actively traded commodities issued by global exchanges
Fundamental Analysis
View fundamental data based on most recent published financial statements